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Females) in the oldest age groups. Conclusion: Use of age- and sex-specific partition 
values enhances the operating characteristics of BNP for detection of LVSD in the com- 
munity. 
BNP@75%Spec Sens/Spec AUC 
Males 45-54 yrs 17 pg/ml 75%/75% 0.88 
Females 45-54 yrs 33 pg/ml ND/75% ND 
Males 55-64 yrs 28 pg/ml 100%/75% 0.94 
Females 55-64 yrs 54 pg/ml 100%/75% 0.97 
Males 65-74 yrs 68 pg/ml 82%/75% 0.89 
Females 65-74 yrs 63 pg/ml 100%/75% 0.90 
Males => 75 yrs 174 pg/ml 78%/75% 0.89 
Females =>75 yrs 168 pg/ml 75%/75% 0.85 
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Background: Brain natriuretic peptide (BNP) and N-terminal atrial natriuretic peptide 
(NT-ANP) have been proposed as screening tests for left ventricular hypertrophy (LVH) 
and LV dysfunction. However, prior studies were limited by small samples and none com- 
pared the diagnostic performance of these peptides in men and women. 
Methods: We evaluated 3441 Framingham Study subjects (1823 women; mean age 59 
years) who attended a routine exam st which echocardiography was performed, and 
plasma SNP and NT-ANP estimated. We examined the contribution of peptide levels for 
detecting LVH, LV dysfunction (fractional shortening [FS}<0.3O), and severe LV dysfunc- 
tion (FS<O.22) by constructing sex-specific ROC curves for each outcome. 
Results: The areas under the ROC curve (AUC) for BNP were consistently higher for 
men compared with women for LVH and LV dysfunction, but not for severe LV dysfunc- 
tion (1"able). Performance characteristics of BNP values that yielded 0.95 specificity are 
shown in the Table. Both BNP and NT-ANP peptides performed well for excluding severe 
LV dysfunction (data for NT-ANP not shown). 
Conclusions: In our large community-based sample, performance of BNP and NT-ANP 
for detection of LV dysfunction and LVH differed between men and women. A high nega- 
tive predictive value for severe LV dysfunction indicates their potential utility for excluding 
severe LV dysfunction, These results can be used to determine the utility of neuropeptide 
screening for LVH and LV dysfunction in asymptomatic people. 
Diagnostic Performance of BNP 
LVH LV Dyefunctlon Severe LV 
Dysfunction 
Men Women Men Women Men Women 
AUC (95% Cl) 0.70 0.57 0.68 0.56 0.84 0.82 
(0.65-0.74) (0.54-0.60)** (0.64-0.72) (0.50-0.52)** (0.75-0.93) (0.61-1.6) 
Sensitivity* 0.30 0.12 0.25 0.t4 0.35 0.43 
PPV/NPV* 0.55/0.87 0.57/0.67 0.44/0.90 0.14/0.95 0.21/0.98 0.04/0.99 
* for specificity =0.95. ** p<0.01 for men vs women. PPV and NPV: positive and nega- 
tive predictive value 
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California, Hartford Hospital, Hartford, Connecticut. 
Background: B-Type Natriuretic peptide (BNP), a protein released from the left ventricle 
in response to volume and pressure ovedoad, has emerged as the first whole blood 
marker for the identification of patients with congestive heart failure (CHF). The 
increased awareness and clinical significance of BNP has warranted the develpoment of 
the first point-of-care assay to rapidly identify and determine severity of CHE Objective: 
To assess the performance of a point-of-care-assay to diagnose and evaluate the sever- 
ity of CHI£ Methodology: Through a prospective, multi-center trial (5 centers), whole 
blood was collected from 1053 patients during the years of 1999-2000. Participants were 
divided into subgroups: normal (n=473), hypertension but no CHF (n=168), and CHF 
(n=804), divided by New York Heart Association (NYHA). Results: The coefficient of vari- 
ation (CV) for intra-assay precision of the test was 9.5% with an analystical sensitivity of 
5.0 pg/ml. 100% of samples were stable up to 8 hours at 4 degrees. Minimum stability at 
room temperature was 4 hours. Patients with no CHF had BNP levels of 9.3 pg/ml and 
was not different from patients with hypertension an no CHF. The median BNP value was 
higher in normal females (12.8) than in males (5.4 pg/ml, P < 0.001) Median BNP levels 
increased with age for both genders. BNP levels increased with severity, but because of 
overlap, could not predict individual NYHA classes. Median BNP levels, for NYHA I-IV 
were 83 pg/ml, 235 pg/ml, 459 pg/ml, and 1119 pg/ml, respectively. The receiver oper- 
ated characteristic curve for all CHF classes was 0.97 ( P< 0.001). Using a decision 
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threshold of 100 pg/ml, the assay demonstrated 82% sensitivity and 99% specificity for 
distinguishing controt and CHF subjects. Conclusion: BNP concentrations obtained from 
whole blood samples are useful in the diagnosis of CHF and staging the severity of dis- 
ease. 
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Background. B-type natriuretic peptide (BNP) is released from ventricular myocytes in 
response to wall tension and has been approved as an aid in the diagnosis of congestive 
heart failure (CHF). We sought to determine the diagnostic utility of BNP in the emer- 
gency department (ED) evalution of dyspnea in a broad spectrum of patients. 
Methods, The BNP Multinational Study was a seven-canter, prospective cohort study of 
1586 patients who presented to the ED with acute dyspnea and had BNP measured with 
a point-of-care device upon ardval. The gold-standard for CHF was adjudicated by two 
independent cardiologists, blinded to BNP results, who reviewed all clinical data and 
standardized CHF scores (NHANES and Framingham). 
Results. Baseline characteristics: mean age 64.4 years, mate 55.8%, female 44.5%, 
Caucasian 49.2%, African American 44.5%, and other race 6.3%. The final diagnosis 
was CHF in 804 (50.7%), a history of CHF but dyspnea due to noncardiac causes in 138 
(8.7%), and not CHF in 644 (40.6%), with mean BNP levels displayed (see figure). The 
most common other diagnoses were asthma and emphysema. The area under the 
receiver operator characteristic curve for the determination of CHF was 0.90, 95% CI 
0.89-0.92. The diagnostic accuracy for BNP was 82.7% for the correct diagnosis at at 
cutoff level of 125 pg/ml. 
Conclusions. In patients with acute dyspnea, using a point-of-care device in the ED, 
measurement of BNP has a high degree of diagnostic accuracy in establishing the diago- 
sis of CHF. 
Mean BNP Upon ED ,a.trival 
n < 0 0001 for all pa l~se  (ompansons 
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